市場調查報告書
商品編碼
1468336
2024-2032 年經導管主動脈瓣植入市場(依手術、最終使用者和地區分類)Transcatheter Aortic Valve Implantation Market by Procedure, End User, and Region 2024-2032 |
2023年全球經導管主動脈瓣植入術(TAVI)IMARC Group規模達63億美元。 10.65% 。冠狀動脈疾病的盛行率不斷上升、微創療法的日益普及以及老年人口的不斷擴大是推動市場發展的一些關鍵因素。
經導管主動脈瓣植入術(TAVI) 是一種用於治療主動脈瓣狹窄的微創外科手術,主動脈瓣狹窄是一種心臟疾病,主動脈瓣變窄,導致從心臟到身體其他部位的血流量減少。在手術過程中,會在患者的腹股溝或胸部切一個小切口。插入導管並引導其穿過股動脈或主動脈到達狹窄的主動脈瓣。由生物材料(例如動物組織或合成材料)製成的人工瓣膜會透過導管展開並定位在狹窄的瓣膜內,該瓣膜會膨脹以取代舊的瓣膜,使血液能夠從心臟自由流動。 TAVI 可在局部麻醉下進行。與傳統手術相比,它的恢復時間更短,併發症風險更低,適合因病重或虛弱而無法進行心臟直視手術的患者。
越來越多的患者患有心臟衰竭、高血壓、冠狀動脈疾病和心血管疾病(CVD),特別是主動脈瓣狹窄,這主要推動了經導管主動脈瓣植入(TAVI)市場的成長。除此之外,由於微創手術(MIS) 具有減少住院時間、縮短復健時間、改善結果和降低整體醫療保健支出等優勢,消費者對微創手術(MIS) 的偏好相對於傳統心臟直視手術的轉變正在創造積極的前景。此外,消費者對主動脈瓣疾病和可用治療方案的認知不斷提高,從而實現早期診斷和及時治療,這有助於市場成長。除此之外,研發 (R&D) 計畫的大量資金以及 TAVI 手術中持續的技術進步(例如生物瓣膜、自膨脹瓣膜和其他創新設備的開發)正在加強市場成長。此外,醫療保健產業的強勁成長、臨床試驗數量的增加、產品的持續創新、老年人口的不斷擴大以及有利的報銷政策都為市場帶來了豐厚的成長機會。
The global transcatheter aortic valve implantation (TAVI) market size reached US$ 6.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 16.1 Billion by 2032, exhibiting a growth rate (CAGR) of 10.65% during 2024-2032. The increasing prevalence of coronary artery disease, the rising adoption of minimally invasive therapies, and the expanding geriatric population represent some of the key factors driving the market.
Transcatheter Aortic Valve Implantation (TAVI) refers to a minimally invasive surgical procedure used to treat aortic stenosis, a heart condition in which the aortic valve narrows, resulting in reduced blood flow from the heart to the rest of the body. During the procedure, a small incision is made in the patient's groin or chest. A catheter is inserted and guided through the femoral artery or the aorta to the narrowed aortic valve. An artificial valve made of biological material, such as animal tissue or synthetic materials, is deployed through the catheter and positioned inside the narrowed valve, which expands to replace the old valve, allowing blood to flow freely from the heart. TAVI can be performed under local anesthesia. Compared to traditional surgery, it has a shorter recovery time and a lower risk of complications and can be performed on patients who are too ill or frail to undergo open-heart surgery.
The growing number of patients suffering from heart failure, hypertension, coronary artery disease, and cardiovascular diseases (CVDs), particularly aortic stenosis, is primarily driving the transcatheter aortic valve implantation (TAVI) market growth. Besides this, the shifting consumer preference for minimally invasive surgery (MIS) over conventional open-heart surgery due to its advantages, such as reduced hospital stay, shorter recovery time, improved outcomes, and lower overall healthcare spending, is creating a positive outlook for the market. Moreover, the escalating consumer awareness about aortic valve disease and available treatment options leading to early diagnosis and timely treatment is contributing to the market growth. In addition to this, the extensive funding in research and development (R&D) initiatives and ongoing technological advancements in the TAVI procedure, such as the development of bioprosthetic valves, self-expanding valves, and other innovative devices, are strengthening the market growth. Furthermore, the bolstering growth of the healthcare industry, the increasing number of clinical trials, continuous product innovations, the expanding geriatric population, and favorable reimbursement policies are presenting remunerative growth opportunities for the market.
IMARC Group provides an analysis of the key trends in each segment of the global transcatheter aortic valve implantation (TAVI) market, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on procedure and end user.
Transfemoral Procedure
Transapical Implantation
Transaortic Implantation
The report has provided a detailed breakup and analysis of the transcatheter aortic valve implantation (TAVI) market based on the procedure. This includes the transfemoral procedure, transapical implantation, and transaortic implantation. According to the report, transfemoral procedure represented the largest segment.
Hospitals
Diagnostic Labs
Ambulatory Surgical Centers
Clinics
Others
A detailed breakup and analysis of the transcatheter aortic valve implantation (TAVI) market based on the end user has also been provided in the report. This includes hospitals, diagnostic labs, ambulatory surgical centers, clinics, and others. According to the report, hospitals accounted for the largest market share.
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for transcatheter aortic valve implantation (TAVI). Some of the factors driving the North America transcatheter aortic valve implantation (TAVI) market included the expanding prevalence of cardiovascular diseases, the rising adoption of minimally invasive therapies, and ongoing technological advancements.
The report has also provided a comprehensive analysis of the competitive landscape in the global transcatheter aortic valve implantation (TAVI) market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Abbott Laboratories, Boston Scientific Corporation, Edwards Lifesciences Corporation, JC Medical Inc. (Genesis Medtech International Private Limited), Medtronic plc, Meril Life Sciences Pvt. Ltd., NVT AG (Biosensors International Group), Venus Medtech (Hangzhou) Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.